Sevoflurane Inhibits Metastasis in Hepatocellular Carcinoma by Inhibiting MiR-665-Induced Activation of the ERK/MMP Pathway.

Recent evidence has indicated that inhalational anesthetics may affect the growth and malignant potential of tumor cells and ultimately influence tumor recurrence after surgery. Sevoflurane, a volatile anesthetic, is used extensively in hepatectomy. However, the effect of sevoflurane on the growth of hepatocellular carcinoma (HCC) cells remains unknown. The aim of this study was to explore the effects of sevoflurane on HCC metastasis and its potential mechanisms in the human HCC cell lines, HepG2 and SMMC7721. HepG2 and SMMC7721 cells were treated with 1.7%, 3.4%, and 5.1 % sevoflurane for 6 h. Cell migration was analyzed using invasion, migration, and scratch assays. Based on previous literature, several microRNAs (miRNAs) were screened to determine regulatory miRNA targets of sevoflurane in HepG2 and SMMC7721 cells; miR-665 was detected as a potential target and overexpressed or inhibited in HepG2 and SMMC7721 cells by a lentiviral system. The p-ERK/MMP pathway was also measured by western blotting. Sevoflurane inhibited the migration and invasion of HCC cells in a dose-dependent manner. It also inhibited miR-665 expression in HCC cells. We further observed that sevoflurane inhibited HCC metastasis via miR-665. Sevoflurane-induced downregulation of miRNA-665 led to phosphorylation of ERK and matrix metalloproteinase (MMP-9) via suppression of SPRED1. These results demonstrated that sevoflurane may inhibit invasion and migration via the p-ERK/MMP-9 signaling pathway in HCC cells.

Introduction

Hepatocellular carcinoma (HCC) is the sixth leading cause of cancer and the third leading cause of cancer-related deaths worldwide . Surgery remains the most effective therapy for HCC. However, recurrence or metastasis remains the most common cause of mortality after the intended curative therapy . Importantly, tumor dissemination may occur during surgery in patients. Anesthesia is a necessary procedure for hepatectomy. It has been reported that anesthesia techniques have an impact on the invasive and migratory abilities of cancer cells, which may affect the prognosis of patients.

The anesthetic agent used in surgery may be an important factor affecting the features of cancer cells. For example, midazolam enhances free radical production and suppresses proliferation and migration of human lung carcinoma cells . In contrast, morphine promotes tumorigenesis and cetuximab resistance in colorectal cancer via activation of epidermal growth factor receptor (EGFR) signaling . Therefore, it is necessary to investigate the role of anesthetics in cancer. Moreover, relative inhibitors may be used with anesthetic agents to reduce the dissemination of tumor cells during surgery.

Sevoflurane is a commercially available anesthetic that is widely used in liver surgery. In recent years, several studies have focused on the effect of sevoflurane on the progression of tumor cells. Kvolik et al. showed that sevoflurane induced late apoptosis in colonic and laryngeal cancer cells. Sevoflurane suppresses lung cancer metastasis by modulating hypoxia-inducible factor-1α (HIF-1α) or cancer-associated platelets[5,6]. It has also been reported that sevoflurane may affect the metastasis of renal cell carcinoma and glioma[8,9]. It is also reported to be associated with the function of breast[10-12], cervical , and colorectal cancer cells . All these studies proved that sevoflurane exhibits a specific impact on the metastasis of cancer cells. However, there have been few reports on the role of sevoflurane in HCC metastasis and its regulatory mechanisms.

MicroRNAs (miRNAs) are short non-coding RNAs (19–22 nucleotides) that function as important regulators of tumor metastasis[15,16]. Currently, 2,693 mature miRNAs have been identified in humans (http://www.mirbase.org/). A fraction of them have been shown to regulate the metastasis of liver cancer[15-17]. Sevoflurane may regulate HCC metastasis by targeting miRNAs. In the present study, we aimed to explore whether sevoflurane has some impact on the metastasis of liver cancer. We also aimed to investigate whether sevoflurane regulates miRNA expression and influences the potential downstream pathways.

Materials and Methods

Cell Lines and Cell Culture

The human HCC cell lines HepG2 and SMMC7721 and the human hepatic cell line L02 were used in this study. HepG2 cells were purchased from the Type Culture Collection (ATCC, Manassas, VA) in the United States. SMMC7721 and L02 were purchased from the Cell Bank of Typical Culture Preservation Committee of Chinese Academy of Science, Shanghai, China. Cells were stored in liquid nitrogen and cultured in an atmosphere containing 5% CO2 at 37°C in high-glucose Dulbecco’s modified Eagle medium (Gibco, Grand Island, NY, USA) supplemented with penicillin (100 IU/ml), streptomycin (100 mg/ml), and 10% fetal bovine serum (FBS; Gibco).

Exposure to Sevoflurane

HepG2, SMMC7721, and L02 cells were treated under the following conditions: 95% air with 5% CO2, 1.7% sevoflurane (Abbott, Abbott Park, IL, USA) mixed with 95% air and 5% CO2, 3.4% sevoflurane mixed with 95% air and 5% CO2, or 5.1% sevoflurane mixed with 95% air and 5% CO2. Cells in the exponential growth phase were seeded in plates and cultured in a CO2 incubator (Thermo Fisher Scientific, Waltham, MA, USA). According to an experimental protocol described previously[18,19], cell culture plates were placed in an airtight glass chamber with inlet and outlet connectors. The inlet port of the chamber was connected to an anesthesia machine (Cicero EM 8060; Dräger, Lübeck, Germany), and sevoflurane was delivered into the chamber using a sevoflurane vaporizer (Sevorane; Abbott) attached to the anesthesia machine. A gas monitor (PM 8060; Dräger) installed with an anesthetic machine at the chamber exit port was used to detect the concentrations of sevoflurane in the chamber. After being exposed to various concentrations of sevoflurane for 6 h, the cells were grown at 37°C in a CO2 incubator for an additional 24 h and then assayed for cell migration and invasion or subjected to molecular analyses.

RNA Isolation and Quantitative Real-Time PCR

RNA was extracted from tissues and cells using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA). The PrimeScript RT reagent Kit (Takara, Kusatsu, Shiga, Japan) was used to perform reverse transcription. Quantitative polymerase chain reaction (PCR) was performed using SYBR Green Master (Takara). U6 was used as a control for miRNA, whereas GAPDH was used as a control for messenger RNA (mRNA). The primers for miR-665, miR-214, miR-206, miR-27a-3p, miR-135b-5p, miR-665, miR-200c, miR-7a, miR-15b, miR-634, and U6 were purchased from RiboBio (Guangzhou, China).

Western Blotting

The RIPA (Radio-Immunoprecipitation Assay) lysis buffer was used to extract total proteins. Proteins were separated by dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto a polyvinylidene fluoride membrane (PVDF) (Roche Life Sciences, Basel, Switzerland). Subsequently, the PVDF membrane was blocked with 5% skim milk. The membrane was incubated with the appropriate primary antibody overnight, followed by incubation with the secondary antibody. The antigen–antibody complex on the membrane was detected using enhanced chemiluminescence reagents (Thermo Scientific, Waltham, MA, USA). The antibodies against Sprouty-related EVH1 domain–containing protein 1 (SPRED1) (ab77079) and β-actin (ab8226) were purchased from Abcam (Cambridge, UK). Antibodies against extracellular signal–regulated kinases (ERKs) (sc-514302), matrix metalloproteinase (MMP-9) (sc-21733), p-ERK (sc-81492), and the corresponding secondary antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

Lentiviral Vector Construction

miR-665-overexpressing lentivirus and miR-665-inhibiting lentivirus, and their corresponding negative control (NC) lentiviral vectors were purchased from GeneChem (Shanghai, China). The SPRED1 wild-type vector and mutant vector were purchased from GeneChem.

Dual-Luciferase Reporter Assay

The wild-type or mutant 3′-untranslated region (UTR) sequences of SPRED1 were inserted into the restriction sites located at the 3′ end of the luciferase gene of the pGL3 vector (GeneChem). The wild-type or mutant sequence is shown in Fig. 4B. The pGL3 vector with the wild-type or mutant 3′-UTR sequences of SPRED1 and pRL-TK vectors were co-transfected into the corresponding cells using Lipofectamine LTX (Invitrogen). Luciferase activity was assayed 48 h after transfection according to the manufacturer’s protocol (Promega, Madison, WI, USA). Firefly and Renilla luciferase activities were detected using a Dual-luciferase Reporter Assay System Kit (Promega) with a Victor X machine (Perkin-Elmer, Boston, MA, USA).

Figure 4.

MiR-665 directly binds to mRNA of SPRED1. (A) The targets of miR-665 were predicted on the basis of well-known public miRNA databases (RNA22-HSA, miRDB, and TARGETSCAN). Venn diagram shows the predicted targets. (B) The wild-type and corresponding mutant sequences of three predicted binding sites in the 3′-UTR of SPRED1 are highlighted. (C, D) Relative luciferase activity was analyzed after the reporter plasmids or mock reporter plasmids were co-transfected into HepG2 cells and SMMC7721 cells infected with or without anti-miR-665 lentivirus. NC: negative control. **P < 0.01.

Cell Viability Assay

Cell viability was determined using the cell counting kit-8 (CCK-8; Dojindo, Kumamoto, Japan). In short, CCK-8 solution was added into each well, and the cells were incubated for 1 h at 37°C in a humidified atmosphere containing 95% air and 5% CO2. The absorbance was detected at 450 nm using a Microplate Reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA).

Lactate Dehydrogenase (LDH) Release Assay

Cells were tested with LDH released using a colorimetric assay kit (Jiancheng Bioengineering Institute). Briefly, the supernatant of cells was removed. After 150 µl of LDH release reagent was added and mixed, the compounds were incubated at 37°C in 5% CO2 for 1 h. Cell cytotoxicity was measured by the absorbance at 490 nm by a Microplate Reader (Bio-Rad Laboratories, Inc.).

Wound Healing Assays

HepG2 and SMMC7721 cells were seeded into 35-mm dishes and cultured under the above-mentioned conditions for 1 day. When the cells reached 100% confluence, a scraped line was created with a 200-µL pipette tip by gliding the tip across the cell surface once. The dishes were washed twice with phosphate-buffered saline (PBS). The medium was replaced with medium without fetal bovine serum (FBS). The dishes were then cultured for 24 h. The speed of wound closure was captured using an inverted microscope (TE-2000S; Nikon, Tokyo, Japan), and the rate of closure was assessed.

Transwell Invasion and Migration Assays

Cells (1 × 105) cultured in medium containing 0.1% bovine serum albumin were seeded into the upper chamber with (invasion assay) or without (migration assay) the Matrigel membrane (BD Biosciences, Franklin Lakes, NJ, USA). Medium containing 10% bovine serum albumin was placed in the chamber. After 24 h of incubation at 37°C, the gel and cells in the upper chamber were carefully removed. Cells adhering to the underside of the membrane were fixed and stained with ethanol and 0.1% crystal violet (Beyotime Institute of Biotechnology, Changsha, China). The number of cells was counted and analyzed.

Statistical Analysis

Data are expressed as mean ± standard deviation (SD) from four independent experiments. The differences between groups were analyzed by Student’s t-test when only two groups were compared or by one-way analysis of variance (ANOVA) for multiple comparisons. A two-tailed P value of less than 0.05 was considered statistically significant.

Results

Sevoflurane Inhibits Migration and Invasion of HCC Cells

To investigate the role of sevoflurane in metastasis of HCC cells, HepG2 and SMMC7721 cells were cultured with different concentrations of sevoflurane (1.7%, 3.4%, and 5.1%). Invasion, migration, and scratch assays were performed to assess the metastatic ability of HCC cells. Invasion assay showed that the number of HepG2 cells under the Transwell membrane of the 1.7% sevoflurane group (106.5 ± 7.4), 3.4% sevoflurane group (79.1 ± 8.8), and 5.1% sevoflurane group (45.6 ± 9.7) were all significantly lower than that of the control group (149.0 ± 5.2, P < 0.01) (Fig. 1A). The number of SMMC7721 cells of the 1.7% sevoflurane group (110.2 ± 11.1), 3.4% sevoflurane group (80.8 ± 7.6), and 5.1% sevoflurane group 53.2 ± 3.7) were significantly lower than that of the control group (150.2 ± 5.0, P < 0.01) (Fig. 1B). The migration assay also showed that the migratory ability of HepG2 and SMMC7721 cells in the control group (256.0 ± 16.37, 181.6 ± 10.45) was higher than that of the 1.7% sevoflurane group (207.6 ± 13.7, P<0.01, 139.6 ± 12.0, P<0.01), 3.4% sevoflurane group (157.0 ± 9.1, 112.2 ± 7.4), and 5.1% sevoflurane group (97.6 ± 8.3, 79.4 ± 6.2) (Fig. 1C, D). Furthermore, the scratch assay showed that the healing rate of HepG2 and SMMC7721 cells in the control group (53.1%. ± 4.3%, 68.5% ± 2.8%) was higher than that of the 1.7% sevoflurane group (53.0% ± 4.3%, 40.61% ± 5.0%), 3.4% sevoflurane group (46.7% ± 2.5%, 35.2% ± 2.3%), and 5.1% sevoflurane group (32.5% ± 2.2%, 20.1% ± 1.7%) (Fig. 1E, F). These data indicated that sevoflurane may suppress the migration and invasion of HCC cells. The inhibitory effect of sevoflurane increased gradually in a dose-dependent manner. Then, we detected the cytotoxicity of sevoflurane on HCC cell lines and normal liver cells with CCK-8 assay and LDH assay. Interestingly, the data showed that sevoflurane can cause HCC cell damage in a dose-dependent manner (Supplementary Fig. 1A–D), while only high concentrations of sevoflurane lead to significant damage to normal liver cells (Supplementary Fig. 1E, F), which is in accordance with previous studies[20,21]. These results suggest that sevoflurane may be more toxic to tumor cells with high proliferative capacity due to some mechanism, which is not fully understood at present.

Figure 1.

Sevoflurane inhibits the metastasis of hepatocellular carcinoma cells. HepG2 cells and SMMC7721 cells of different groups were incubated with different concentrations of sevoflurane. (A, B) Transwell assays with a Matrigel were used to detect the metastasis of HepG2 cells and SMMC7721 cells of each group. The cell number in the visual field of each group was counted and compared. (C, D) Transwell assay without the Matrigel was employed to detect migration of HepG2 cells and SMMC7721 cells. The cell number in the visual field was counted and compared. (E, F) The migration capacity of HepG2 cells and SMMC7721 cells in each group was detected with a wound healing assay. The wound healing speed was compared after incubation with different concentrations of sevoflurane for 24 h. The width of the scratch was measured at 0 and 24 h time points. The wound healing speed is represented as a histogram. *P < 0.05; **P < 0.01.

Sevoflurane Inhibits MiR-665 Expression in HCC Cells

To determine whether miRNAs are regulated by sevoflurane, real-time PCR was employed to determine the expression of miRNAs associated with sevoflurane exposure under other pathological states[22,23]. We observed that miR-665 was significantly suppressed more than two folds in the 5.1% sevoflurane group than NC in HepG2 cells (Fig. 2A). And similarly results also can be seen in SMMC7721 cells (Fig. 2B). Thus, we speculated that sevoflurane may inhibit HCC metastasis by suppressing miR-665.

Figure 2.

Sevoflurane suppresses miR-665 in a dose-dependent manner. miRNA expression in HepG2 cells (A) and SMMC7721 cells (B) was detected with real-time polymerase chain reaction. miR-665 overexpression vector or miR-665 inhibition vector (anti-miR-665) was transfected into HepG2 cells (C) and SMMC7721 cells (D), respectively, to alter miR-665 expression in HepG2 cells. NC: negative control. #P ≥ 0.05; *P < 0.05; **P < 0.01.

Sevoflurane Inhibits Metastasis of HCC via MiR-665

As sevoflurane (5.1%) inhibited metastasis and miR-665 expression more than two folds, we used miR-665 overexpression or miR-665 inhibition lentiviral vectors in these two groups. After 5.1% sevoflurane treatment, the expression of miR-665 decreased. This decline was reversed by miR-665 overexpression. Meanwhile, the expression of miR-665 in the sevoflurane 5.1% + NC group was mimicked in the control + anti-miR-665 group (Fig. 2C, D). Invasion, migration, and scratch assays were performed to evaluate the metastasis of HCC cells in these groups. The invasion assay showed that the invasive ability of the HepG2 and SMMC7721 cells in 5.1% sevoflurane + miR-665 group (162.0 ± 8.4, 122.6 ± 2.1) was similar to that of the control + NC group (154.2 ±7.8, 128.0 ± 6.3) and was significantly higher than that of the 5.1% sevoflurane + NC group (47.0 ± 4.3, 79.0 ± 10.3). The invasive ability of the control + anti-miR-665 group (52.0 ± 5.8, 71.2 ± 13.3) was lower than that of the control + NC group (154.2 ± 7.8, 128.0 ± 6.3) and was similar to that of the 5.1% sevoflurane +NC group (47.0 ± 4.3, 79.0 ± 10.3) (Fig. 3A, B). The migration assay also showed that after normalizing the expression of miR-665, the migration of HepG2 and SMMC7721 cells was recovered. After inhibiting miR-665 expression, the migration of HepG2 and SMMC7721 cells was also suppressed (Fig. 3C, D). The wound healing assay showed that the closure speed of the 5.1% sevoflurane + miR-665 group (67.5% ± 5.9%, 74.7% ± 2.1%) was similar to that of the control + NC group (67.6% ± 5.9%, 70.3% ± 4.6%) and was higher than that of the 5.1% sevoflurane + NC group (40.0% ± 4.2%, 35.1% ± 3.3%). The closure speed of the control + anti-miR-665 group (38.0% ± 2.5%, 37.5% ± 1.6%) was lower than that of the control + NC group (67.6% ± 5.9%, 70.3%± 4.6%) (Fig. 3E, F). These results showed that overexpression or inhibition of miR-665 expression may reverse or mimic the effect of sevoflurane on HCC metastasis, indicating that sevoflurane can inhibit metastasis of HCC cells via miR-665.

Figure 3.

Reintroduction of miR-665 abrogates the tumor suppressive ability of sevoflurane in HepG2 cell and SMMC7721 cells. Transwell assay with Matrigel (A), Transwell assay without Matrigel (B) and wound healing assays (C) were used to detect metastasis and migration capacities of HepG2 cells and SMMC7721 cells. Histogram represents the statistical results of corresponding assays. NC: negative control. #P ≥ 0.05; *P < 0.05; **P < 0.01.

Sevoflurane-Induced Downregulation of MiRNA-665 Leads to Phosphorylation of ERK and MMP-9 Expression via the Suppression of SPRED1

To identify the target of miR-665, we screened the predicted target mRNAs of miR-665 from three miRNA databases. These predicted targets contained intersection elements and are represented as a Venn diagram in Fig. 4A. Relevant literature about these 94 common predictive targets was reviewed to identify mRNAs that may function as tumor suppressors. SPRED1 was a predictive mRNA target with three predicted binding sites (Fig. 4B). Mutant or wild-type 3′-UTR of SPRED1 was cloned on the respective PGL3 vectors containing the firefly luciferin gene, as shown in Fig. 4B. The wild-type or mutant PGL3 vector was transfected with the pRL-TK vector into HepG2 and SMMC7721 cells. The dual-luciferase reporter assay showed that the intensity of firefly luciferin was significantly suppressed in the wild-type group than the vector group and mutant group, but the intensity of firefly luciferin was similar to the vector group and mutant group because of the inhibition of miR-665. The intensity of firefly luciferin in the three groups was equal after inhibiting miR-665 expression (Fig. 4C, D). These results indicate that miR-665 may directly bind to the 3′-UTR of SPRED1. SPRED1 is an important inhibitor of the Ras MAPK pathway in cancer ; thus, we determined the expression of important metastasis-related proteins by western blotting in cells treated with different concentrations of sevoflurane. Concordant with the increase in sevoflurane concentrations, p-ERK and MMP-9 (an endopeptidase that digests basement-membrane type IV collage) expression decreased (Fig. 5A–C). This result indicated that sevoflurane activates the MAPK pathway. We reversed miR-655 expression to evaluate whether miR-655 expression may reverse the effect of sevoflurane. MiR-665 overexpression attenuated the function of sevoflurane, whereas miR-665 inhibition mimicked it (Fig. 5D–H). Taken together, the present findings suggest that sevoflurane can regulate metastasis of HCC via the miR-665/SPRED1/p-ERK/MMP-9 pathway (Fig. 6).

Figure 5.

MiR-665 targets SPRED1 and activates ERK and MMP-9. HepG2 cells were incubated with different concentrations of sevoflurane. Western blot bands indicate p-ERK and MMP-9 expression in each group (A). The gray value of p-ERK/β-actin and MMP-9/β-actin was measured and is shown in the figure (B, C). (D) Western blot shows SPRED1, ERK, ERK phosphorylation status, and MMP expression in HepG2 cells treated with sevoflurane or upon reinfection with miRNA expression vectors. The gray value of SPRED1/β-actin, ERK/β-actin, p-ERK/β-actin, and MMP-9/β-actin is shown in the figure (E, H). ERK: extracellular signal–regulated kinase; MMP-9: matrix metalloproteinase-9; NC: negative control. *P < 0.05; **P < 0.01.

Figure 6.

Schematic representation of the role and molecular mechanism of sevoflurane in HCC. Sevoflurane is one of the commonly used anesthesia drugs which can assist surgeons in completing the removal of the primary tumor. For tiny HCC lesions or metastatic liver cancer cells, sevoflurane can eliminate the inhibition of tumor suppressor protein SPRED1 by decreasing the expression of miR-665 in liver cancer cells, reducing the phosphorylation level of ERK, and ultimately decreasing MMP-9 expression, thus inhibiting the metastasis ability of tumor cells. Sevoflurane can not only meet the anesthesia needs for surgery, but also have a certain antitumor effect on HCC. HCC: hepatocellular carcinoma; ERK: extracellular signal–regulated kinase; MMP-9: matrix metalloproteinase-9.

Discussion

General anesthesia is routinely employed for hepatectomy. Recently, an increasing number of studies have shown that anesthetics used in surgery exhibit positive or negative effects on tumor recurrence[25,26]. It is important for anesthesiologists to choose anesthetics that have anticancer effects during cancer surgery to reduce the risk of recurrence and metastasis in patients. Sevoflurane is a widely used analgesic in clinical surgery. It is suitable for anesthesia induction and maintenance because of its rapid recovery time and relatively low risk.

The aim of this study was to explore the effect of sevoflurane on the metastasis of HCC cells, as the mechanism of this drug is still unknown. To simulate the clinical anesthesia setting, HepG2, SMMC7721, and L02 cells were treated for 6 h with three commonly used concentrations of sevoflurane. Translational findings based on a clinical trial revealed that sevoflurane protects hepatocytes from ischemic injury by reducing reactive oxygen species–associated signaling in hematopoietic stem cells . Also, 2% sevoflurane does not trigger hepatocyte apoptosis in rat; it has no significant hepatotoxicity . Even after 3 days of 3% sevoflurane exposure, there was no evidence of hepatic or renal toxicity both from histologic studies and from serum biomarkers . Sevoflurane can increase proliferation and migration in an in vitro model of breast cancer . A recent study showed that the biological processes of HCC cells were suppressed by sevoflurane, and 4% sevoflurane exerts antiapoptotic activity and inhibits cell viability and invasive behavior in vitro . In this study, we demonstrated that inhalation of sevoflurane inhibits the metastasis of HCC cells by inhibiting miR-665/SPRED1/ERK/MMP-9 axis. Sevoflurane is more toxic to HCC cells than to normal liver cells. These results indicated that sevoflurane has certain antitumor activity. However, the mechanism of sevoflurane inhibits the expression of miR-665, the cause of inducing tumor cytotoxicity, and the EC50 of sevoflurane is still not fully understood. Further research is still needed.

MiRNAs are involved in regulating various cell processes, such as cell proliferation, migration, invasion, and apoptosis[30,31]. Several miRNAs have been reported to participate in tumor progression, and thus, these functional miRNAs are considered potential therapeutic targets for cancer treatment[32,33]. MiR-665 has been reported to be closely associated with pivotal signaling pathways in the pathogenesis of lung cancer and hepatocellular carcinoma[34,35]. Upregulated miR-665 expression independently predicts poor prognosis of lung cancer and facilitates tumor cell proliferation, migration, and invasion . Another study revealed that it promotes HCC cell migration, invasion, and proliferation by decreasing Hippo signaling by targeting PTPRB (Protein Tyrosine Phosphatase Receptor Type B) both in vivo and in vitro . Widely known as a tumor suppressor, SPRED1 inhibits the Ras/Raf-1/ERK pathway and reduces the expression levels of MMP-9 and MMP-2 . The SPRED1 cascade is also involved in tumor growth and metastasis in breast cancer .

Conclusion

In conclusion, we identified that miR-665 targets the SPRED1/p-ERK/MMP9 pathway and participates in the metastasis of HCC, and sevoflurane was able to inhibit the invasion and migration of HCC cells by inhibiting miR-665-induced activation of the p-ERK/MMP pathway in HCC. Our study supported that sevoflurane inhalation used in surgical anesthesia may reduce the postoperative metastasis. However, more clinical evidences are needed to confirm this hypothesis. This study will help elucidate the pharmacological effects of inhaled general anesthetics such as sevoflurane and emphasize that the selection of volatile anesthetics for patients with HCC during surgery is clinically significant.

Click here for additional data file.

Supplemental material, sj-tif-1-cll-10.1177_09636897221104447 for Sevoflurane Inhibits Metastasis in Hepatocellular Carcinoma by Inhibiting MiR-665-Induced Activation of the ERK/MMP Pathway by Xiaoyan Zhu, Chuchu Peng, Zhiyong Peng, Ruimin Chang and Qulian Guo in Cell Transplantation